You are here: Home / Cancer Research Network / Honorary Associate Professor Qihan Dong / Honorary Associate Professor Qihan Dong 

Honorary Associate Professor Qihan Dong

Honorary Associate Professor
Medicine, Central Clinical School
Bosch Institute

D06 - Blackburn Building
The University of Sydney
NSW 2006 Australia

T: +61 2 9515 5186
F: +61 2 9516 1273
E:

Biographical details

Associate Professor Dong was trained as a Physician but pursued a full time research career after being awarded PhD in 1992 from The University of Sydney. He then continued as a Fogarty Fellow at the National Institutes of Health, USA. On returning to Sydney in 1996, he was appointed as the Head of the Cancer Biology Group. The Group has grown from 1 PhD student to now include 10 members. Dong has taken 15 students (9 PhD and 6 Master) since his appointment as Group leader in 1996. Ten of them have completed and now work in biomedical field. Dong also takes responsibility to teach Senior Registrar from Royal Prince Alfred Hospital. Two Gordon Craig Fellows have spent one year (full time) in Dong’s laboratory to conduct basic research on prostate cancer. He is the overseas supervisor for Chinese students sponsored by National China Scholar Council (3 have completed their studies and returned to China). Dong was awarded one of the 12 inaugural Career Development & Support NSW Cancer Institute Fellowships in 2005.He has published 54 papers (total citations of 1,672). Thirty-eight papers were published after his appointment as the Group Head in peer-reviewed international journals with an average Impact factor of 4.5. He is the first or senior/corresponding author on 77% of them. His work has led to lodgement of an International Patent (Northern America, EU, Japan and Australia).

Back to Top

Research interests

Qihan Dong is the Head of the Cancer Biology Group and aims at understanding the mechanisms underlying survival and proliferation of cancer cells.

Back to Top

Teaching areas

Dong is the guest lecturer on Prostate Cancer to University of Sydney senior pathology students (since 2008) and to the Master Course for Surgery (2011).

Back to Top

Current national competitive grants*

2010

Pharmacological Targeting via AKT, PTEN, and TGF-beta Pathway Integration using Novel Therapeutics
Richardson D, Assinder S, Dong Q
NHMRC Project Grant ($611,875 over 3 years)

* Grants administered through the University of Sydney

Back to Top

Keywords

Cell biology; Lipid metabolism; Cancer

Back to Top

Publications

2010 | 2009 | 2008 | 2006

2010

   
  • Niknami, M., Vignarajan, S., Yao, M., Hua, S., Witting, P., Kita, Y., Shimizu, T., Sved, P., Patel, M., Dong, Q. (2010), Decrease in expression or activity of cytosolic phospholipase A(2)alpha increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochimica et biophysica acta. 1801(7), 731-7. [Abstract]
  • Scott, K., Sajinovic, M., Hein, J., Nixdorf, S., Galettis, P., Liauw, W., de Souza, P., Dong, Q., Graham, G., Russell, P. (2010), Emerging roles for phospholipase A(2) enzymes in cancer. Biochimie. 92(6), 601-10. [Abstract]
  • Assinder, S., Au, E., Dong, Q., Winnick, C. (2010), A novel splice variant of the beta-tropomyosin (TPM2) gene in prostate cancer. Molecular carcinogenesis. 49(6), 525-31. [Abstract]
  • Singh, J., Xie, C., Yao, M., Hua, S., Vignarajan, S., Jardine, G., Hambly, B., Sved, P., Dong, Q. (2010), Food extracts consumed in Mediterranean countries and East Asia reduce protein concentrations of androgen receptor, phospho-protein kinase B, and phospho-cytosolic phospholipase A(2)alpha in human prostate cancer cells. Journal of Nutrition. 140(4), 786-791. [Abstract]
  • Yao, M., Taylor, R., Richards, M., Sved, P., Wong, J., Eisinger, D., Xie, C., Salomon, R., Risbridger, G., Dong, Q. (2010), Prostate-Regenerating Capacity of Cultured Human Adult Prostate Epithelial Cells. Cells, tissues, organs. 191(3), 203-12. [Abstract]
  • Young, L., Dong, Q. (2010), Targeted Amplification of Mutant Strands for Efficient Site-Directed Mutagenesis and Mutant Screening. In: Methods in Molecular Biology: In Vitro Mutagenesis Protocols. (pp.147-155).United States: Humana Press.

2009

   
Back to Top
  • Niknami, M., Dong, Q., Witting, P. (2009), Pitfalls in the use of arachidonic acid oxidation products to assign lipoxygenase activity in cancer cells. Free radical research. 43(10), 951-6. [Abstract]
  • Richards, A., McGeechan, K., Niknam, M., Salomon, R., Kurek, C., Dong, Q., Patel, M. (2009), Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?. ANZ Journal of Surgery. 79(9), 641-647. [Abstract]
  • Salomon, R., Young, L., Macleod, D., Yu, X., Dong, Q. (2009), Probasin promoter-driven expression of ID1 is not sufficient for carcinogenesis in rodent prostate. Journal of Histochemistry and Cytochemistry. 57(6), 599-604. [Abstract]
  • Niknami, M., Patel, M., Witting, P., Dong, Q. (2009), Molecules in focus: Cytosolic phospholipase A(2)-alpha. The international journal of biochemistry & cell biology. 41(5), 994-7. [Abstract]
  • Assinder, S., Dong, Q., Mangs, H., Richardson, D. (2009), Pharmacological Targeting of the Integrated AKT, PTEN and TGF-{beta} Pathways in Prostate Cancer. Molecular pharmacology. 75(3), 429-36. [Abstract]
  • Assinder, S., Dong, Q., Kovacevic, Z., Richardson, D. (2009), The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal. 417(2), 411-421. [Abstract]

2008

   
Back to Top
  • Patel, M., Singh, J., Niknami, M., Kurek, C., Yao, M., Lu, S., Maclean, F., King, N., Gelb, M., Scott, K., Russell, P., Boulas, J., Dong, Q. (2008), Cytosolic Phospholipase A2-{alpha}: A Potential Therapeutic Target for Prostate Cancer. Clinical Cancer Research. 14(24), 8070-8079. [Abstract]
  • Patel, M., Kurek, C., Dong, Q. (2008), The arachidonic acid pathway and its role in prostate cancer development and progression. The Journal of Urology. 179(5), 1668-1675. [Abstract]
  • Nikinami, M., Patel, M., Witting, P., Dong, Q. (2008), Aberrant activation of arachidonic acid and eicosanoid pathways-targets for treating prostate cancer. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. 2, 9-15.

2006

   
Back to Top
  • Lim, W., Tan, B., Zhu, Y., Zhou, S., Armstrong, J., Li, Q., Dong, Q., Chan, E., Smith, D., Verma, C., Tan, S., Duan, W. (2006), The very C-terminus of PRK1/PKN is essential for its activation by RhoA and downstream signaling. Cellular signalling. 18(9), 1473-81. [Abstract]
  • Dong, Q., Patel, M., Scott, K., Graham, G., Russell, P., Sved, P. (2006), Oncogenic action of phospholipase A(2) in prostate cancer. Cancer letters. 240, 9-16. [Abstract]
  • Singh, J., Manickam, P., Shmoish, M., Natik, S., Denyer, G., Handelsman, D., Gong, D., Dong, Q. (2006), Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate. Cancer letters. 237, 298-304. [Abstract]
  • Young, L., Salomon, R., Au, W., Allan, C., Russell, P., Dong, Q. (2006), Ornithine decarboxylase (ODC) expression pattern in human prostate tissues and ODC transgenic mice. The Journal of Histochemistry and Cytochemistry. 54(2), 223-229. [Abstract]